Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBT (2021 - 2025)

Krystal Biotech (KRYS) has disclosed EBT for 5 consecutive years, with $51.1 million as the latest value for Q4 2025.

  • Quarterly EBT rose 5.19% to $51.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $189.5 million through Dec 2025, up 98.7% year-over-year, with the annual reading at $189.5 million for FY2025, 98.7% up from the prior year.
  • EBT hit $51.1 million in Q4 2025 for Krystal Biotech, up from $48.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $80.7 million in Q3 2023 to a low of -$50.0 million in Q1 2022.
  • Historically, EBT has averaged $4.4 million across 5 years, with a median of -$7.3 million in 2021.
  • Biggest five-year swings in EBT: crashed 215.99% in 2022 and later skyrocketed 4577.79% in 2025.
  • Year by year, EBT stood at -$21.8 million in 2021, then crashed by 46.99% to -$32.1 million in 2022, then soared by 133.25% to $10.7 million in 2023, then surged by 356.13% to $48.6 million in 2024, then increased by 5.19% to $51.1 million in 2025.
  • Business Quant data shows EBT for KRYS at $51.1 million in Q4 2025, $48.0 million in Q3 2025, and $46.8 million in Q2 2025.